{"id":"azd5213","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD5213 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is thought to be beneficial for patients with type 2 diabetes.","oneSentence":"AZD5213 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:46.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01548287","phase":"PHASE2","title":"A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Mild Cognitive Impairment, Mild Alzheimer's Disease","enrollment":164},{"nctId":"NCT01928381","phase":"PHASE2","title":"Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-11","conditions":"Diabetic Neuropathy, Painful; Diabetic Neuropathies","enrollment":150},{"nctId":"NCT01904773","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"Tourette Syndrome","enrollment":29},{"nctId":"NCT01121302","phase":"PHASE1","title":"Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Tolerability","enrollment":88},{"nctId":"NCT01171105","phase":"PHASE1","title":"Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Healthy","enrollment":73},{"nctId":"NCT01194986","phase":"PHASE1","title":"Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Brain Distribution of [11C]AZ12807110 and AZD5213","enrollment":13},{"nctId":"NCT01335451","phase":"PHASE1","title":"Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-04","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD5213","genericName":"AZD5213","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD5213 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}